Sep 03, 2021 06:30 PM (GMT+8) · EqualOcean
Financial Associated Press, September 3 (Xinhua), the top nine biology announced that the company publicly delisted the 30% equity of Maixin biology held by Sinopharm investment, and the delisting price was 948 million yuan. Maixin biology is a holding subsidiary of the company, mainly engaged in immunohistochemical diagnosis business. The transaction will increase the company's shareholding in Maixin biology.